Skip to main content
NCEL
NASDAQ Life Sciences

NewcelX Appoints Big Pharma Diabetes Leader Dr. Julien Boisdron to Scientific Advisory Board

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.37
Mkt Cap
$9.527M
52W Low
$1.89
52W High
$337
52W Position info
25% above low
Off High info
99% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

NCEL sits 25% above its 52-week low of $1.89 on light trading volume (0.2× avg).

Summary

NewcelX Ltd. has appointed Dr. Julien Boisdron, a prominent diabetes expert from a major Swiss pharmaceutical company, to its Scientific Advisory Board, bolstering expertise for its lead Type 1 Diabetes program.


Key Events · Executive and Board Changes · NCEL

  • Key Appointment to Scientific Advisory Board

    NewcelX announced the appointment of Dr. Julien Boisdron, MD, to its Scientific Advisory Board (SAB). Dr. Boisdron is currently the Chief Medical Officer for a major Swiss-based multinational large cap pharma company, bringing over two decades of global leadership in diabetes care.

  • Strategic Guidance for Lead Program

    Dr. Boisdron will provide high-level strategic guidance for IsletRx, NewcelX's lead stem-cell-derived islet cell therapy program for insulin-dependent Type 1 Diabetes. His expertise will support translational strategy, patient adoption, health-system integration, and global commercialization frameworks as the program advances toward clinical trials.

  • Enhanced Diabetes Expertise

    This appointment significantly strengthens NewcelX's expertise in metabolic and regenerative medicine, particularly in Type 1 Diabetes, which is a core clinical focus for the company.


Analysis · NCEL · Life Sciences

The appointment of Dr. Julien Boisdron, a seasoned diabetes expert and Chief Medical Officer at a major Swiss pharma, significantly strengthens NewcelX's Scientific Advisory Board. His extensive experience in diabetes innovation and global medical leadership is directly relevant to the company's lead IsletRx program for Type 1 Diabetes. This strategic addition provides crucial guidance as NewcelX advances its cell-based therapy towards clinical trials and potential commercialization, enhancing the company's credibility and strategic direction in a key therapeutic area.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NCEL was trading at $2.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $1.89 to $337.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NCEL - Latest Insights

NCEL
Nov 09, 2026, 9:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.34
Real-time Price: $2.54 info
Change: +$0.200 (+9%) info
Market Cap: $13.675M info
NCEL
Nov 04, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.64
Real-time Price: $2.54 info
Change: -$0.100 (-4%) info
Market Cap: $13.675M info
NCEL
Sep 18, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.15
Real-time Price: $2.54 info
Change: -$0.610 (-19%) info
Market Cap: $13.675M info
NCEL
Aug 03, 2026, 4:29 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $2.54 info
Change: -$0.7199 (-22%) info
Market Cap: $13.675M info
NCEL
Jul 31, 2026, 9:11 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $2.54 info
Change: -$0.980 (-28%) info
Market Cap: $13.675M info